News Analysis Report: Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR.A), EnteroMedics Inc (NASDAQ:ETRM)

On Monday, Shares of Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR.A), included 9.78% and shut at $9.32 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $8.98 and $9.32. The business’ commercial center capitalization is $66.24 Billion with the aggregate fabulous loads of 5.60 billion. Petróleo Brasileiro S.A. – Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets. The company’s Refining, Transportation and Marketing segment is involved in the refining, logistics, transport, and trading of crude oil and oil products, in addition to exports ethanol and invests in petrochemical companies. This segment also engages in the extraction and processing of shale. The company’s Gas and Power segment engages in the transportation and trade of natural gas and liquid natural gas; generation and trade of electricity; holding interests in natural gas transportation and distribution, and thermoelectric power plants; and fertilizer business. Its Biofuels segment is involved in the production of biodiesel and its co-products, in addition to in the investment, production, and trading of ethanol, sugar, and the electric power generated from sugarcane bagasse. The company’s Distribution segment distributes oil products, ethanol, and vehicle natural gas in Brazil to retail, commercial, and industrial customers, in addition to other fuel wholesalers.

Shares of EnteroMedics Inc (NASDAQ:ETRM), subtract -12.39% and shut at $0.0451 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $0.04 and $0.05. The association’s commercial center capitalization is $5.21 million with the general uncommon loads of 113.115 million. EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has partnershipwith Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003.

Leave a Reply

Your email address will not be published. Required fields are marked *